A detailed analysis of UK data from a global obesity study (the ACTION-IO study) has shown that, on average, people with obesity (PwO) in the UK were struggling with their weight for nine years before they sought help from a healthcare professional/HCP, much longer than the global average of six years. This delay puts PwO at additional risk of developing obesity-related conditions such as type 2 diabetes (T2D), obstructive sleep apnoea (OSA) and cancer. Additionally, more than half of the PwO had never discussed their weight with an HCP.
The latest findings from the annual Scandinavian Obesity Surgery Registry (SOReg) report could challenge existing recommendations and clinical practice for bariatric surgery and type 2 diabetes (T2DM) patients, according to the authors of a summary paper of the report, ‘Bariatric Surgery: There Is a Room for Improvement to Reduce Mortality in Patients with Type 2 Diabetes’, published in Obesity Surgery.
Males with obesity suffering from hypogonadism who have testosterone injections lost weight and saw improvement in a wide range of other metabolic parameters, according to research led by Dr Farid Saad, Consultant, Medical Affairs Andrology, Bayer AG, Berlin, Germany, and Gulf Medical University School of Medicine, Ajman, UAE, and colleagues. The study was presented at the European and International Congress on Obesity (ECOICO 2020).
Individuals whose overweight or obesity is diagnosed in hospital are 60% more likely to die compared to the general population, according to a nationwide Danish study that followed over 1.9 million people for up to 40 years, presented at The European and International Congress on Obesity. The risk of dying was highest within the first year of diagnosis but remained markedly higher for individuals with hospital-diagnosed overweight or obesity over the whole study period.
Data presented in a special COVID-19 session at the European and International Congress on Obesity (ECOICO 2020) suggests that there are overlaps between the immunological disturbances found in both COVID-19 disease and patients with obesity, which could explain the increased disease severity and mortality risk faced by patients with obesity and COVID-19. Since fat mass generally increases with ageing, this might also partly explain the increased death risk in older patients.
An online survey of nearly 3,000 UK adults suggests that people would prefer health professionals to use the words "weight", "unhealthy weight", and "overweight" when discussing weight status, and reveals parents' desire to avoid their children being referred to as "fat", "extra-large", or "plus size".
More than half of adults have found it difficult to manage their weight during the COVID-19 lockdown, according to the results of an online survey involving over 800 UK adults, presented at The European and International Congress on Obesity. Most of the respondents said their difficulties stemmed from increased snacking, not exercising as much as usual, increased anxiety or stress and not being able get hold of healthier food.
Findings from a positron emission tomography (PET) brain imaging study of the amygdala reveals that low levels of the enzyme aromatase, which catalyses oestrogen biosynthesis, are associated with a higher body mass index and lower self-control, as measured by a standard personality test.
Americans are less likely to blame people with obesity for their condition and are more likely to believe that obesity has a medical explanation now than three years ago, according to the results of two online surveys involving more than 6,000 UK and US adults. The outcomes were presented at the European and International Congress on Obesity (ECOICO 2020).
Scientists at Joslin Diabetes Center have delivered a proof of concept for a novel cell-based therapy for obesity that would by transplanting human brown-like (HUMBLE) fat cells, human white fat cells that have been genetically modified to become similar to heat-generating brown fat cells. The finding were reported in the paper, ‘CRISPR-engineered human brown-like adipocytes prevent diet-induced obesity and ameliorate metabolic syndrome in mice’, published in Science Translational Medicine.